The news of Citigroup maintaining a Buy rating on Mersana Therapeutics is positive for the stock. However, the lowering of the price target from $15 to $10 may create some uncertainty among investors, potentially offsetting the positive sentiment. As a result, the short-term impact on MRSN's stock price is expected to be neutral.